Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 2
1975 3
1976 3
1977 10
1978 5
1979 15
1980 10
1981 3
1982 3
1983 9
1984 2
1985 10
1986 2
1987 3
1988 4
1989 7
1990 3
1991 2
1994 4
1997 2
1998 1
1999 3
2000 3
2001 1
2002 1
2003 5
2004 9
2005 7
2006 7
2007 4
2008 5
2009 2
2010 7
2011 5
2012 7
2013 4
2014 3
2015 1
2016 2
2017 1
2019 1
2020 4
2021 2
2022 3
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

195 results

Results by year

Filters applied: . Clear all
Page 1
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang XM; SURMOUNT-2 investigators. Garvey WT, et al. Lancet. 2023 Aug 19;402(10402):613-626. doi: 10.1016/S0140-6736(23)01200-X. Epub 2023 Jun 26. Lancet. 2023. PMID: 37385275 Clinical Trial.
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I; SAVOR-TIMI 53 Steering Committee and Investigators. Scirica BM, et al. N Engl J Med. 2013 Oct 3;369(14):1317-26. doi: 10.1056/NEJMoa1307684. Epub 2013 Sep 2. N Engl J Med. 2013. PMID: 23992601 Free article. Clinical Trial.
Whither pathogenetic treatments for diabetic polyneuropathy?
Boulton AJ, Kempler P, Ametov A, Ziegler D. Boulton AJ, et al. Among authors: ametov a. Diabetes Metab Res Rev. 2013 Jul;29(5):327-33. doi: 10.1002/dmrr.2397. Diabetes Metab Res Rev. 2013. PMID: 23381942 Review.
Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs.
Schernthaner G, Karasik A, Abraitienė A, Ametov AS, Gaàl Z, Gumprecht J, Janež A, Kaser S, Lalić K, Mankovsky BN, Moshkovich E, Past M, Prázný M, Radulian G, Smirčić Duvnjak L, Tkáč I, Trušinskis K. Schernthaner G, et al. Among authors: ametov as. Cardiovasc Diabetol. 2019 Aug 31;18(1):115. doi: 10.1186/s12933-019-0920-3. Cardiovasc Diabetol. 2019. PMID: 31472683 Free PMC article.
Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes.
Schernthaner G, Shehadeh N, Ametov AS, Bazarova AV, Ebrahimi F, Fasching P, Janež A, Kempler P, Konrāde I, Lalić NM, Mankovsky B, Martinka E, Rahelić D, Serafinceanu C, Škrha J, Tankova T, Visockienė Ž. Schernthaner G, et al. Among authors: ametov as. Cardiovasc Diabetol. 2020 Oct 23;19(1):185. doi: 10.1186/s12933-020-01154-w. Cardiovasc Diabetol. 2020. PMID: 33097060 Free PMC article. Review.
195 results